PT - JOURNAL ARTICLE AU - Zoe Swank AU - Grégoire Michielin AU - Hon Ming Yip AU - Patrick Cohen AU - Diego O. Andrey AU - Nicolas Vuilleumier AU - Laurent Kaiser AU - Isabella Eckerle AU - Benjamin Meyer AU - Sebastian J. Maerkl TI - A high-throughput microfluidic nano-immunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultra-low volume dried blood samples AID - 10.1101/2020.10.07.20208280 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.07.20208280 4099 - http://medrxiv.org/content/early/2020/10/25/2020.10.07.20208280.short 4100 - http://medrxiv.org/content/early/2020/10/25/2020.10.07.20208280.full AB - Novel technologies are needed to facilitate large-scale detection and quantification of SARS-CoV-2 specific antibodies in human blood samples. Such technologies are essential to support seroprevalence studies, vaccine clinical trials, and to monitor quality and duration of immunity. We developed a microfluidic nano-immunnoassay for the detection of anti-SARS-CoV-2 IgG antibodies in 1024 samples per device. The method achieved a specificity of 100% and a sensitivity of 98% based on the analysis of 289 human serum samples. To eliminate the need for venipuncture, we developed low-cost, ultra-low volume whole blood sampling methods based on two commercial devices and repurposed a blood glucose test strip. The glucose test strip permits the collection, shipment, and analysis of 0.6 µL whole blood easily obtainable from a simple fingerprick. The nano-immunoassay platform achieves high-throughput, high sensitivity and specificity, negligible reagent consumption, and a decentralized and simple approach to blood sample collection. We expect this technology to be immediately applicable to current and future SARS-CoV-2 related serological studies and to protein biomarker diagnostics in general.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the European Research Council under the European Union's Horizon 2020 research and innovation program Grant 723106 (SJM), SNF Project grant 182019 (SJM), SNF NRP 78 Covid-19 grant 198412 (SJM, IE, and BM), EPFL (SJM) and a grant from the Private Foundation of the Geneva University Hospital (IE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was waived by the ethical committee of the University Hospital of Geneva in accordance with local regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available on MedRxiv as supplemental files.